Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Huang

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Therapeutics and Clinical Risk Management|November 10, 2009
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrheaHoonmo L Koo, Herbert L Dupont, David B Huang
Antimicrobial Agents and Chemotherapy|January 16, 2019
<i>In Vitro</i> Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure InfectionsStephanie Noviello, Sophie Magnet, Stephen Hawser, et al.
The Journal of Infection|September 1, 2004
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccinesDavid B Huang, Jashin J Wu, Stephen K Tyring
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 29, 2018
Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection modelDavid B Huang, Jee Hyun Park, Timothy M Murphy
The American Journal of Tropical Medicine and Hygiene|December 26, 2003
Association of virulence factor-positive and -negative enteroaggregative Escherichia coli and occurrence of clinical illness in travelers from the United States to MexicoDavid B Huang, Zhi-Dong Jiang, Herbert L Dupont
Scandinavian Journal of Infectious Diseases|August 17, 2004
Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDSDavid B Huang, Jashin J Wu, Richard J Hamill
Antiviral Research|October 23, 2004
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responsesJashin J Wu, David B Huang, Stephen K Tyring
Comprehensive Psychiatry|March 27, 2003
Psychopathology among persons responding to participation as normal controls in behavioral research studiesDavid B Huang, Hoonmo Koo, Don Dougherty, et al.
Journal of Medical Microbiology|March 11, 2009
The prevalence and virulence characteristics of enteroaggregative Escherichia coli at an urgent-care clinic in the USA: a case-control studyDavid Cennimo, Atif Abbas, David B Huang, et al.
Journal of Medical Microbiology|July 2, 2013
Lysins: the arrival of pathogen-directed anti-infectivesMina Pastagia, Raymond Schuch, Vincent A Fischetti, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Therapeutics and Clinical Risk Management|November 10, 2009
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrheaHoonmo L Koo, Herbert L Dupont, David B Huang
Antimicrobial Agents and Chemotherapy|January 16, 2019
<i>In Vitro</i> Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure InfectionsStephanie Noviello, Sophie Magnet, Stephen Hawser, et al.
The Journal of Infection|September 1, 2004
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccinesDavid B Huang, Jashin J Wu, Stephen K Tyring
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 29, 2018
Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection modelDavid B Huang, Jee Hyun Park, Timothy M Murphy
The American Journal of Tropical Medicine and Hygiene|December 26, 2003
Association of virulence factor-positive and -negative enteroaggregative Escherichia coli and occurrence of clinical illness in travelers from the United States to MexicoDavid B Huang, Zhi-Dong Jiang, Herbert L Dupont
Scandinavian Journal of Infectious Diseases|August 17, 2004
Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDSDavid B Huang, Jashin J Wu, Richard J Hamill
Antiviral Research|October 23, 2004
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responsesJashin J Wu, David B Huang, Stephen K Tyring
Comprehensive Psychiatry|March 27, 2003
Psychopathology among persons responding to participation as normal controls in behavioral research studiesDavid B Huang, Hoonmo Koo, Don Dougherty, et al.
Journal of Medical Microbiology|March 11, 2009
The prevalence and virulence characteristics of enteroaggregative Escherichia coli at an urgent-care clinic in the USA: a case-control studyDavid Cennimo, Atif Abbas, David B Huang, et al.
Journal of Medical Microbiology|July 2, 2013
Lysins: the arrival of pathogen-directed anti-infectivesMina Pastagia, Raymond Schuch, Vincent A Fischetti, et al.
Pageof 9